Skip to Content
Search Menu

Flere patienter med myelomatose kan nu behandles med CAR-T

Overlæge Charlotte Toftmann Hansen har store forventninger til den udvidede anbefaling af ciltacabtagene autoleucel (cilta-cel) til behandling af myelomatose i anden og tredje behandlingslinje. Det betyder længere PFS, OS og livskvalitet for patienterne.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

New Opportunities to Improve Care for People Living with Sickle Cell Disease

/ Jan Andreasen
ASH25
Johan Gustafsson

Towards Identifying Which CLL Patients with Richter Transformation Respond to Immune Checkpoint Inhibitor Therapy

/ Johan Gustafsson
ASH25 Play the Video 4:04

Higher-Than-Recommended Lenalidomide Dosing Is Safe in Transplant-Eligible Newly Diagnosed Multiple Myeloma with Renal Impairment

/ Frida Bugge Askeland / Jan Andreasen
ASH25Multiple myeloma

Low-dose Decitabine/Cedazuridine Reduces Toxicity While Preserving Efficacy in Low-risk MDS

/ Jan Andreasen
ASH25
Signe Modvig

Danish Research Identifies Promising New Target for Preventing CNS Relapse in ALL

/ Signe Modvig
ASH25 Play the Video 03:30

BPd Preserved or Improved Quality of Life in Patients with RRMM

/ Paul G. Richardson / Jan Andreasen
ASH25Myeloma
Ingrid Cecilia Glimelius

Novel Clinical Data in Mantle Cell Lymphoma Highlighted in ASH 2025 Oral Session

/ Ingrid Cecilia Glimelius
ASH25 Play the Video 5:57
Ingrid Cecilia Glimelius

Nordic Study Uncovers a New Minimally Invasive Biomarker for Low-Risk Mantle Cell Lymphoma

/ Ingrid Cecilia Glimelius
ASH25 Play the Video 2:57
Henrik Hjorth-Hansen

Improving CML Outcomes: Nordic CML Study Group Shares New ASH 2025 Insights

/ Henrik Hjorth-Hansen
ASH25Lymphoma Play the Video 4:10
Back to top